Literature DB >> 18793680

Enhancement of latent inhibition in patients with chronic schizophrenia.

Gilad Gal1, Yael Barnea, Lior Biran, Shlomo Mendlovic, Tamir Gedi, Michal Halavy, Joram Feldon, Shmuel Fennig, Yechiel Levkovitz.   

Abstract

OBJECTIVES: Latent inhibition (LI) refers to the retarding effects of inconsequential stimulus preexposure on subsequent conditioning to that stimulus, and reflects the organism's capacity to ignore irrelevant stimuli. LI is disrupted in schizophrenia patients, due to faster learning of the association between the conditioned stimulus (CS) and an unconditioned stimulus (US). It was recently proposed that LI has an additional pole of abnormality indicated by LI persistence.
METHODS: Two experiments were performed to test this hypothesis. Both experiments applied a new within-subject, visual recognition LI procedure in which the association between a cue (CS) and the target (US) is acquired. In Exp 1 the task was applied to healthy volunteers (n=21). In Exp 2 chronic schizophrenia patients (n=19) were compared to control subjects (n=20).
RESULTS: In Exp 1 the subjects showed LI in the initial trials of cue-target pairings, and an attenuation of the phenomenon at later trials. In Exp 2 control subjects showed a pattern of response comparable to the subjects of Exp 1, while the patients showed LI only on the later trials of the task.
CONCLUSIONS: This result suggests that patients with chronic schizophrenia showed LI persistence. The possible advantages of the new LI paradigm are discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18793680     DOI: 10.1016/j.bbr.2008.08.023

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  9 in total

1.  Impaired contextual fear-conditioning in MAM rodent model of schizophrenia.

Authors:  Kathryn M Gill; Sarah A Miller; Anthony A Grace
Journal:  Schizophr Res       Date:  2017-09-18       Impact factor: 4.939

Review 2.  Contribution of nonprimate animal models in understanding the etiology of schizophrenia.

Authors:  Noah L Lazar; Richard W J Neufeld; Donald P Cain
Journal:  J Psychiatry Neurosci       Date:  2011-07       Impact factor: 6.186

3.  Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?

Authors:  Ariane T Orosz; Joram Feldon; Andor E Simon; Leonie M Hilti; Kerstin Gruber; Benjamin K Yee; Katja Cattapan-Ludewig
Journal:  Schizophr Bull       Date:  2010-01-15       Impact factor: 9.306

4.  Catecholaminergic depletion within the prelimbic medial prefrontal cortex enhances latent inhibition.

Authors:  A J D Nelson; K E Thur; C A Marsden; H J Cassaday
Journal:  Neuroscience       Date:  2010-07-07       Impact factor: 3.590

Review 5.  Accounting for individual differences in human associative learning.

Authors:  Nicola C Byrom
Journal:  Front Psychol       Date:  2013-09-04

6.  Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition.

Authors:  Kiri T Granger; Jennifer Ferrar; Sheryl Caswell; Mark Haselgrove; Paula M Moran; Angela Attwood; Jennifer H Barnett
Journal:  Front Psychiatry       Date:  2021-04-16       Impact factor: 4.157

7.  Disruption of Long-Term Depression Potentiates Latent Inhibition: Key Role for Central Nucleus of the Amygdala.

Authors:  Donovan M Ashby; Carine Dias; Lily R Aleksandrova; Christopher C Lapish; Yu Tian Wang; Anthony G Phillips
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

Review 8.  Human latent inhibition: Problems with the stimulus exposure effect.

Authors:  N C Byrom; R M Msetfi; R A Murphy
Journal:  Psychon Bull Rev       Date:  2018-12

Review 9.  The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity.

Authors:  Samuel J Millard; Carrie E Bearden; Katherine H Karlsgodt; Melissa J Sharpe
Journal:  Neuropsychopharmacology       Date:  2021-09-29       Impact factor: 7.853

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.